20 August 2026
Latham Advises KaliVir Immunotherapeutics on US$14 Million Series A Extension Financing
Advising firms
Deal team
3 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Eli Curi Lead | Latham & Watkins LLP | Partner | Emerging Companies & Growth | New York |
| Saem Kim | Latham & Watkins LLP | Associate | Emerging Companies & Growth | Not stated |
| Adithi Iyer | Latham & Watkins LLP | Associate | Emerging Companies & Growth | Not stated |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 14m (US$14 million)
- What the figure measures
- Total transaction value
- Client
- KaliVir Immunotherapeutics, Inc.Issuer
- Counterparties
- Company K Partners (Investor)
SV Investment (Investor)
Flexus Partners (Investor)
Nextrans (Investor)
Quad Investment Management (Investor)